Bavarian Biotech Report 2011/2012 (7MB) - Bio M

apoGene GmbH & Co. KGBIOTECH AGRO, FOOD, ENVIRONMENTKeywords: Xenotransplantation, Knock Out, Tissue Engineering / Cell CultureapoGene is focused on the field of xenotransplantation. Rabbits and pigsare genetically modified (transfer, knock out and recombination of endogenousgenes) for influencing the different steps of the rejection process after xenotransplantationof animals tissues and organs. We are also investigating theexpression of endogenous retroviral sequences after xenogenetic transfer.For the development of knock out animals we have developed and patentedan alternative strategy, the so called screen-out of hemozygote carriers offunctional defects in natural or mutagenized populations. The technique willalso be very interesting for the establishment of animal models for basicand applied research.Contact:Prof. Dr. Gottfried BremLarezhausen 2D-86567 HilgertshausenPhone: +49 (0) 8250 9279010Fax: +49 (0) 8250 9279019E-Mail: gottfried.brem@apogene-gmbh.deInternet: www.apogene-gmbh.deAssign GroupCROKeywords: Analysis, Clinical Research, Logistics, Monitoring, Medical Writing,Pharmacology, Toxicology, Insourcing, Outsourcing, RecruitingThe Assign Group, an international expert in pharmaceutical developmentoffering full service globally to Biotechnology, Pharmaceutical and MedicalDevice Companies. We support pharmaceutical development from preclinicalto clinical phase I to IV. Our broad expertise covers the entire developmentprocess, reduces the clients development time at affordable budgetand supports the projects to become a success. We are right there whereyou need us.Assign Life Science Resourcing’s network (ALSR) matches the most qualifiedcandidates and clients.Contact:Verena KöpkeFraunhoferstr. 22D-82152 MartinsriedPhone: +49 (0) 89 741206-80Fax: +49 (0) 89 741206-88E-Mail: verena.koepke@assigngroup.comInternet: www.assigngroup.comAstellas Pharma GmbHPHARMA & CHEMICAL INDUSTRYKeywords: Drug Development, Antibiotics, Allergy, Autoimmune Diseases,Immune Therapy, Infectious Diseases, InflammationContact:Dr. Martin MarhoeferAstellas Pharma Inc. was formed in April 2005 from a merger withYamanouchi and Fujisawa. Astellas Pharma is Japan’s second largestpharmaceutical company and is headquartered in Tokio. It has operations inEurope, Asia, North America and Japan. Astellas is focused on four keytherapy areas: Transplantation, urology, dermatology, and anti-infectives.Astellas employs approximately 3,300 people in Europe across Sales andMarketing, Research & Development and Manufacturing. Astellas has 19Sales and Marketing Affiliates, 3 plants and 1 R&D site in Europe. AstellasEurope is headquartered just outside London in Staines. The Germanheadquarters are based in Munich. Located here are Sales, Marketing andMedical. The product portfolio includes therapies in transplantation, urology,dermatology, asthma/COPD, cardiology, antibiotics and gastroenterology.Astellas Pharma GmbH Munich employs approximately 350 peopleincluding 225 sales representatives.Georg-Brauchle-Ring 64-66D-80992 MünchenPhone: +49 (0) 89 4544-1440Fax: +49 (0) 89 4544-5440E-Mail: info@de.astellas.comInternet: www.astellas.de39